How to access Amondys 45 from the UAE — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A UAE family of a boy with Duchenne muscular dystrophy (DMD) whose genotyping confirms an exon-45-skip-amenable mutation may receive a prescription for Amondys 45 (casimersen) from their treating paediatric neurologist. Amondys 45 is FDA-approved, manufactured by Sarepta Therapeutics, and is an antisense oligonucleotide designed to restore partial dystrophin production in DMD patients amenable to exon 45 skipping — roughly 8% of the DMD population. In the UAE, Amondys 45 is not locally registered, which is why your paediatric neurologist is likely guiding you toward the Ministry of Health and Prevention (MoHAP) named-patient import pathway.

This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Amondys 45 is a phosphorodiamidate morpholino oligomer (PMO) administered by weekly intravenous infusion, indefinitely. Eligibility is strictly genotype-gated: your child's DMD gene mutation must be confirmed by accredited genetic testing as amenable to exon 45 skipping. Treatment requires a paediatric neurologist with DMD experience, a day-infusion facility, and ongoing monitoring including renal function, cardiac assessment, and motor-function scales (NSAA, 6MWT). Dosing is weight-based and long-term; this is an indefinite commitment rather than a finite course.

Is Amondys 45 legally importable into the UAE?

Yes — through the MoHAP named-patient import framework. Parallel authority operates in Abu Dhabi through the Department of Health (DoH) and in Dubai through the Dubai Health Authority (DHA), depending on where the prescribing facility is located.

The named-patient mechanism allows a UAE-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is available, (c) the physician takes clinical responsibility, and (d) the importing party documents chain of custody end to end. For exon-45-amenable DMD in the UAE, there is no locally registered exon-skipping alternative, making the clinical rationale clear once genotype is confirmed.

How the pathway works, step by step

1. Consultation with your paediatric neurologist. Confirmation of DMD diagnosis and exon-45-skip-amenable genotype, with baseline NSAA, 6MWT, cardiac, and renal assessments documented.
2. Treatment-centre identification. A UAE tertiary hospital with paediatric neurology and infusion-day-unit capacity is confirmed as the administering site.
3. MoHAP named-patient application. Your physician or the hospital pharmacy files the application with clinical rationale, genotyping report, patient reference, and chain-of-custody plan.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Amondys 45 from Sarepta's authorised distribution channel.
5. Shipment. The product ships under chain-of-custody and manufacturer handling conditions to the administering hospital pharmacy.
6. Arrival and first infusion. The hospital administers the weekly infusion and establishes the ongoing schedule; Reserve Meds coordinates rolling refills.

What documentation your physician needs

Your physician will typically need to provide:

• A clinical rationale letter confirming DMD diagnosis, exon-45-skip-amenable mutation, baseline motor and cardiac status, and Amondys 45 as the indicated treatment
• Verification of their UAE medical licence
• A copy of the accredited DMD genetic-testing report
• Patient identifier (anonymised reference where possible)
• An administration and monitoring plan including weekly infusion scheduling and long-term follow-up

Reserve Meds provides a physician documentation kit with the templates MoHAP (or DoH/DHA) reviewers expect to see for rare-paediatric-neurology named-patient imports, including the exon-skipping genotype gate central to Amondys 45 eligibility.

Costs and timing

Amondys 45 is weight-dependent in dosing, so annual cost scales with the child's body weight. Indicative 2026 US cash-pay annual cost sits in a broad range of roughly USD 300,000 to over USD 1,000,000 depending on weight, with adolescents and older children at the upper end. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.

Indicative timing — not guaranteed — for the first infusion after cohort intake opens is approximately 14–28 days from the moment a complete MoHAP application is submitted. Subsequent weekly supply runs on a rolling refill schedule once the pathway is established.

Reserve Meds is in pre-launch. Fulfilment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A culturally-aware note: DMD is an X-linked condition, and in the UAE the emotional weight often falls heavily on mothers and maternal grandmothers who carry the carrier-status question into family planning conversations. Our concierge coordination is designed to include whichever family members the caregiver designates, and we can brief extended family members on refill logistics, travel between emirates, and the long-term nature of this therapy.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Amondys 45 specifically, we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and for MoHAP (or DoH/DHA) review, tailored to exon-skipping eligibility.
• Logistics. Chain-of-custody shipment coordination to the administering hospital pharmacy on a weekly-refill cadence.
• Concierge case lead. A named point of contact for the family, managing long-term refill logistics and weight-based dose adjustments as the child grows.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating paediatric neurologist. We operate on a waitlist basis during our pre-launch phase.

Frequently asked

Is this legal in the UAE? Yes, when executed through the MoHAP (or DoH/DHA) named-patient framework with appropriate documentation. Cross-border named-patient import for rare-paediatric-disease therapies is a recognised mechanism. See our trust and compliance page.

Is Amondys 45 a cure? No. Amondys 45 is a disease-modifying therapy that restores partial dystrophin expression in exon-45-amenable DMD patients. Your paediatric neurologist will discuss realistic outcome expectations and long-term monitoring.

What if my son's mutation is not exon-45-amenable? Amondys 45 is exon-45-specific. Other exon-skipping therapies target exons 51 and 53; if your son's mutation is amenable to a different exon skip, that product would be the relevant candidate. Your neurologist's genotype report guides the choice.

Can my son travel internationally while on treatment? Yes, but weekly infusion scheduling needs careful coordination around travel. Our concierge team helps plan refill timing and provides documentation to support cross-border travel with the medication and supporting prescriptions.

Will insurance or government coverage apply? Cash-pay is the default. Some UAE private insurers consider rare-disease imports case by case, and some Emirati nationals may access public-sector pathways; we supply documentation for submission but do not process insurance or public-payer claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Amondys 45 coordination in the UAE.

Composite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.